Research Paper Volume 16, Issue 2 pp 1218—1236
Development and validation of a combined cuproptosis and immunogenic cell death prognostic model for diffuse large B-cell lymphoma
- 1 Department of Hematology, Qilu Hospital of Shandong University, Jinan 250012, China
- 2 Department of Geriatrics, Hematology and Oncology Unit, Qilu Hospital of Shandong University, Jinan 250012, China
Received: May 6, 2023 Accepted: November 17, 2023 Published: January 26, 2024
https://doi.org/10.18632/aging.205399How to Cite
Copyright: © 2024 Wang et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Background: Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma worldwide with a high degree of heterogeneity. Cuproptosis and immunogenic cell death (ICD) have been considered to be vital for tumor progression. However, current understanding of cuproptosis and immunogenic cell death in DLBCL is still very limited. We aim to explore a prognostic model combining cuproptosis and immunogenic cell death in DLBCL.
Methods: Pearson’s correlation analysis was utilized to acquire lncRNAs associated with cuproptosis and immunogenic cell death. Prognostic biomarker identification and model construction involved the use of univariate Cox regression, least absolute shrinkage and selection operator (LASSO) Cox regression, and multivariate Cox regression. We assessed the predictive capability of the risk model by conducting Kaplan-Meier analysis and time-dependent ROC analysis. The analysis and comparison of immune infiltration and drug sensitivity were conducted in this study. Moreover, RT-qPCR was employed to validate the expression of lncRNAs associated with cuproptosis and immunogenic cell death in DLBCL cell lines.
Results: We identified 4 prognosis-related lncRNAs (ANKRD10-IT1, HOXB-AS1, LINC00520 and LINC01165) that were correlated with cuproptosis and immunogenic cell death. The model was verified to have a good and independent predictive ability in the prognostic prediction of DLBCL patients. Moreover, significant difference was observed in immune infiltration and drug sensitivity between high- and low-risk groups.
Conclusion: Our discoveries could enhance the comprehension of the role of cuproptosis and ICD in DLBCL, potentially offering novel viewpoints and knowledge for personalized and precise treatment of DLBCL individuals.
Abbreviations
DLBCL: Diffuse large B-cell lymphoma; ICD: Immunogenic cell death; LASSO: Least absolute shrinkage and selection operator; RT-qPCR: Real-time quantitative PCR; CR: Complete remission; CRGs: Cuproptosis-related genes; IRGs: Immunogenic cell death-related genes; CRLs: Cuproptosis-related lncRNAs; IRLs: Immunogenic cell death-related lncRNAs; CRIRLs: Cuproptosis-related and immunogenic cell death-related lncRNAs; PCA: Principal component analysis; OS: Overall survival; ROC: Receiver operating characteristic; ssGSEA: Single sample gene set enrichment analysis; GDSC: Genomics of Drug Sensitivity in Cancer.